Abeona provides new data to FDA on EB-101 ahead of meeting
Abeona Therapeutics has submitted a data briefing package on its cell therapy candidate EB-101 to the U.S. Food and Drug Administration (FDA) ahead of a meeting with the agency planned for this month. The meeting’s purpose is to discuss Abeona’s planned application seeking approval of EB-101 to treat recessive …